Findings from a study presented at the 2021 SGO Virtual Annual Meeting on Women's Cancer, frail patients with ovarian cancer who undergo surgery at institutions with higher surgical volume have lower…
In a session presented at the 2021 SGO Annual Meeting on Women’s Cancer Rebecca Kristeleit, PhD, UCL Cancer Institute, London, shared findings from the ARIEL4 study on rucaparib versus chemotherapy.
True or false: Type O cervicovaginal microbiota has been linked to higher risk for ovarian cancer.
True or false: Nivolumab improved overall survival versus gemcitabine/pegylated liposomal doxorubicin in platinum-resistant ovarian cancer.
Quiz: Is Significant Clinical Benefit Derived From Maintenance Olaparib for BRCA-Mutated Ovarian Cancer?
True or false: Long-term olaparib maintenance significantly extended PFS over placebo in BRCA-mutated ovarian cancer.
Nivolumab did not improve survival versus gemcitabine and pegylated liposomal doxorubicin (GEM/PLD) in platinum-resistant ovarian cancer in the phase 3 NINJA trial.
Patients with BRCA-mutated ovarian cancer given maintenance olaparib after first-line platinum-based chemotherapy had extended rates of PFS and RFS, according to findings from the SOLO1 trial.
According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
Focusing on patient-centered outcomes from the ARIEL3 trial, rucaparib extended PFS in the maintenance setting for ovarian cancer despite toxicities.